Vanberra Signal
Free trial

GEn1E

Curated by Signal

Developer of therapeutics for the treatment of inflammatory and rare diseases

Life Sciences Technologygen1e.com

Overview

Developer of therapeutics for the treatment of inflammatory and rare diseases. The company's platform is utilizing the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform to create novel therapies for rare and inflammatory diseases. The lead candidate molecule is "GEn-1124"- for lung chronic conditions and other candidate molecules are in the research and discovery phase.

Key facts

Founded
2018
Headquarters
Palo Alto, United States
Stage
Sign up to view
Industry
Life Sciences Technology

Business model

3 products and services
Sign up to view

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

  • Cleared

    Online platform providing personalized consultation and treatment for allergies

    Life Sciences TechnologyNew York City, United States

  • Flore

    Provide nutritional supplements to improve gut health

    Life Sciences TechnologySan Diego, United States

  • Cognision

    Provider of ERP/q EEG headset

    Life Sciences TechnologyLouisville, United States

About GEn1E

What does GEn1E do?

Developer of therapeutics for the treatment of inflammatory and rare diseases.

Where is GEn1E headquartered?

GEn1E is headquartered in Palo Alto, United States.

When was GEn1E founded?

GEn1E was founded in 2018.

Which sector is GEn1E in?

GEn1E operates in Life Sciences Technology.

Who are GEn1E's competitors?

Companies similar to GEn1E include Cleared, Flore, and Cognision.